Agile Therapeutics (NASDAQ:AGRX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a research report report published on Friday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Maxim Group raised Agile Therapeutics from a hold rating to a buy rating and set a $5.00 target price on the stock in a research report on Friday, September 22nd.

Agile Therapeutics Price Performance

Shares of AGRX opened at $2.12 on Friday. The company has a market capitalization of $5.33 million, a price-to-earnings ratio of -0.16 and a beta of 1.81. Agile Therapeutics has a fifty-two week low of $1.65 and a fifty-two week high of $16.00. The business’s 50-day moving average is $1.96 and its 200-day moving average is $2.74.

Institutional Investors Weigh In On Agile Therapeutics

Hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC boosted its holdings in Agile Therapeutics by 281.3% in the 1st quarter. Renaissance Technologies LLC now owns 621,200 shares of the specialty pharmaceutical company’s stock valued at $130,000 after purchasing an additional 458,300 shares during the period. BlackRock Inc. increased its holdings in shares of Agile Therapeutics by 538.6% during the third quarter. BlackRock Inc. now owns 303,799 shares of the specialty pharmaceutical company’s stock worth $91,000 after buying an additional 256,227 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Agile Therapeutics in the 4th quarter valued at $32,000. Jane Street Group LLC acquired a new stake in shares of Agile Therapeutics during the 2nd quarter valued at $108,000. Finally, State Street Corp acquired a new position in shares of Agile Therapeutics in the second quarter valued at approximately $32,000. 7.52% of the stock is currently owned by institutional investors and hedge funds.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.